ccr5 receptor antagonist ccr5 receptor antagonist ccr5 receptor antagonists are a class of small molecules that antagonize the ccr5 receptor. the c-c motif chemokine receptor ccr5 is involved in the process by which hiv, the virus that causes aids, enters cells. hence antagonists of this receptor are entry inhibitors and have potential therapeutic applications in the treatment of hiv infections. the life cycle of the hiv presents potential targets for drug therapy, one of them being the viral entry pathway. ccr5 and cxcr4 are the main receptors involved in the hiv entry process. these receptors belong to the seven transmembrane g-protein-coupled receptor (gpcr) family and are predominantly expressed on human t-cells, dendritic cells and macrophages, langerhans cells. they play an important role as co-receptors that hiv type 1 (hiv-1) uses to attach to cells before viral fusion and entry into host cells. hiv isolates can be divided into r5 and x4 strains. r5 strain is when the virus uses the co-receptor ccr5 and x4 strain is when it uses cxcr4. the location of ccr5 receptors at the cell surface, both large and small molecules have the potential to interfere with the ccr5-viral interaction and inhibit viral entry into human cells. history since the discovery of hiv in the 1980s, remarkable progress has been made in the development of novel antiviral drugs. the trigger for the discovery of the ccr5 antagonists was the observation that a small percentage of high-risk populations showed either resistance or delayed development of the disease. this population was found to have a mutation (ccr5-δ32) in the gene that codes for the ccr5 receptor which results in almost complete resistance against hiv-1 infection and scientists then discovered the key role of the cell surface receptors ccr5 and cxcr4 in successful viral fusion and infection. in 1996, it was demonstrated that ccr5 serves as a co-receptor for the most commonly transmitted hiv-1 strains, r5. this type of virus is predominant during the early stages of infection and remains the dominant form in over 50% of late stage hiv-1 infected patients, however r5 strains can eventually evolve into x4 as the disease progresses. this information led to the development of a new class of hiv drugs called ccr5 antagonists. mechanism of action figure 1 hiv entry into cd4+ cell via ccr5 co-receptor. hiv enters host cells in the blood by attaching itself to receptors on the surface of the cd4+ cell. viral entry to the cd4+ cell begins with attachment of the r5 hiv-1 glycoprotein 120 (gp120) to the cd4+ t-cell receptor, which produces a conformational change in gp120 and allows it to bind to ccr5, thereby triggering glycoprotein 41 (gp41) mediated fusion of the viral envelope with the cell membrane and the nucleocapsid enters the host cell (figure 1). ccr5 co-receptor antagonists prevent hiv-1 from entering and infecting immune cells by blocking ccr5 cell-surface receptor. small molecule antagonists of ccr5 bind to a hydrophobic pocket formed by the transmembrane helices of the ccr5 receptor. they are thought to interact with the receptor in an allosteric manner locking the receptor in a conformation that prohibits its co-receptor function. drug development as mentioned, the ccr5 receptor is a g-protein coupled receptor (gpcr). before the discovery of ccr5's role in hiv infection, many pharmaceutical companies had already built a substantial collection of compounds that target gpcrs. some of these compounds would prove to be a starting point for ccr5 antagonist medicinal chemistry, but would need optimization to improve ccr5 selectivity and potency, and to improve pharmacokinetic properties. a significant problem was the affinity of available screening hits for the herg ion channel; inhibition of herg leads to qt interval prolongation, which can increase the risk of developing fatal ventricular arrhythmias. many ccr5 antagonists have been studied by pharmaceutical companies, but few of them have actually reached human efficacy studies; for example astrazeneca, novartis, merck, and takeda have used their gprc-targeting compound collections to develop a potent ccr5 antagonist, but none of them have reached clinical trials. three pharmaceutical companies were in competition to be the first to have a small molecule ccr5 antagonist approved: glaxosmithkline (gsk) with their compound aplaviroc, schering-plough with vicriviroc, and pfizer with maraviroc. all of the compounds reached clinical trials in humans; only maraviroc has been approved by the u.s. food and drug administration (fda). leronlimab leronlimab is a humanized monoclonal antibody targeted against the ccr5 receptor found on t lymphocytes of the human immune system and many types of cancers. it is being investigated as a potential therapy in the treatment of hiv infection, graft versus host disease (nct02737306) and metastatic cancer (nct03838367). the united states food and drug administration (fda) has designated leronlimab for fast-track approval. in february 2008, the drug entered phase 2 clinical trials and a phase 3 trial was begun in 2015. in february 2018 cytodyn inc reported that the primary endpoint has been achieved in the pro 140 pivotal combination therapy trial in hiv infection. leronlimab is being developed by cytodyn inc. in may 2007, results from the phase i clinical trial of the drug demonstrated "potent, rapid, prolonged, dose-dependent, highly significant antiviral activity" for leronlimab. participants in the highest-dosing group received 5 milligrams per kilogram and showed an average viral load decrease of -1.83 log10. on average, reductions of greater than -1 log10 per millilitre were maintained for between two and three weeks, from only a single dose of the drug. the largest individual hiv rna reductions ranged up to -2.5 log10 among patients receiving both the 2 and 5 mg/kg doses. leronlimab is a lab-made antibody that functions as an entry inhibitor. leronlimab binds to the ccr5 receptor on the cd4 cells, and interferes with hiv's ability to enter the cell. leronlimab, a humanized form of a pa14 antibody, is a chemokine-receptor ccr5 monoclonal antibody and can inhibit ccr5 tropic hiv-1 at concentrations that do not antagonize the natural activity of ccr5 in vitro. hiv-1 entry is mediated by the hiv-1 envelope glycoproteins gp120 and gp41. the gp120 will bind cd4 and the ccr5co receptor molecule, and this triggers gp41-mediated fusion of the viral and cellular membranes. ccr5 is hence needed for the entry of the virus and this infection of healthy cells. leronlimab, the anti-ccr5 monoclonal antibody, can stop hiv from entering the cell and stop viral replication. it prevents the virus-cell binding at a distinct site in the ccr5 co-receptor without interfering with its natural activity. unlike other entry inhibitors, pro 140 is a monoclonal antibody. the mechanism of inhibition is competitive rather than allosteric. as such, it must be injected to be effective. however, once inside the body, pro 140 binds to ccr5 for >60 days, which may allow for dosing as infrequently as every other week. compared to highly-active antiretroviral therapy which has been shown to have treatment-related toxicities for hiv-infected patients, pro140 has no multi-drug resistance or toxicities. in february 2018, cytodyn reported that the primary endpoint has been achieved in the pro 140 pivotal combination therapy trial in hiv infection and will continue for an additional 24 weeks (end of august 2018) with pro 140 weekly subcutaneous injections and optimized art. the report discloses that a single 350 mg subcutaneous injection of pro 140 resulted in a hiv-1 rna viral load reduction greater than 0.5log or 68% within one week compared with those who received a placebo. the primary efficacy endpoint results were presented at asm microbe 2018. in the pivotal trial of leronlimab in combination with standard anti-retroviral therapies in hiv-infected treatment-experienced patients, 81% of patients completing trial achieved hiv viral load suppression of < 50 cp/ml. recent approved drugs for this population range from 43% after 24 weeks to 45% after 48 weeks with viral load suppression of < 50 cp/ml. in march 2019, cytodyn filed with the us fda the first part of the bla for leronlimab (pro140) as a combination therapy with haart in hiv. in may 2020, the company filed its bla with potential fda approval in 4q'20. cytodyn is conducting an investigative monotherapy trial of leronlimab (pro140) for hiv. if successful, once per week self-administered leronlimab would represent a paradigm shift in treatment of hiv. cytodyn is investigating the use of leronlimab in various solid tumors. on february 18, 2019, cytodyn announced it will begin 8 pre-clinical studies on melanoma cancer, pancreatic, breast, prostate, colon, lung, liver, and stomach cancer. this has the potential to lead to 8 phase ii clinical studies with leronlimab in the cancer arena. on november 23, 2018, cytodyn received fda approval of its ind submission and allowed to initiate a phase ib/ii clinical trial for metastatic triple-negative breast cancer (mtnbc) patients. on february 20, 2019, cytodyn announced that leronlimab was able to reduce by more than 98% the incidence of human breast cancer metastasis in a mouse xenograft model for cancer through six weeks with leronlimab. the temporal equivalency of the murine 6 weeks study may be up to 6 years in humans. in may 2019, the u.s. food and drug administration (fda) granted fast track designation for leronlimab for use in combination with carboplatin for the treatment of patients with ccr5-positive mtnbc. in july 2019, cytodyn announced the dosing of first mtnbc patient under compassionate use. simultaneously, the phase ib/ii trial for treatment-naïve mtnbc patients is active and anticipates top line data in 2020. if successful, the data from treatment-naïve mtnbc patients could serve as the basis for potentially seeking accelerated us fda approval. a study demonstrated leronlimab reduced the number and size of new human breast cancer metastasis in a mouse model and reduced the size of established metastasis thereby extending survival. in may 2019, cytodyn initiated pre-clinical study of leronlimab to prevent nash. aplaviroc figure 2. molecular structure of aplaviroc and its lead compound figure 3 molecular structure of vicriviroc and its lead compounds aplaviroc is originated from a class of spirodiketopiperazine derivatives. figure 2 shows the molecular structure of the lead compound and the final compound aplaviroc. the lead compound showed good potency in blocking ccr5 in a number of r5 hiv strains and against multi-drug resistant strains. the problem with this compound was not its ccr5 selectivity but the oral bioavailability. this led to further development of the molecule and the result was a compound named aplaviroc. unfortunately, despite the promising preclinical and early clinical results, some severe liver toxicity was observed in the treatment of naïve and treatment-experienced patients that led to the discontinuation in further development of aplaviroc. vicriviroc schering-plough identified an active compound during screening. figure 3 shows the molecular structure of the lead compound, intermediate compound, and the final compound vicriviroc. the lead compound contained a piperazine scaffold and was a potent muscarinic acetylcholine receptor (m2) antagonist with modest ccr5 activity. the changes that were made on the left hand side of the lead compound and the addition of a methyl group on the piperazine group ((s)-methylpiperazine) resulted in the intermediate compound that had good affinity for ccr5 receptors but very little affinity for muscarinic activity, however, the compound did show affinity for the herg ion channel. further reconstruction led to the development of the final compound vicriviroc, when schering discovered that the pyridyl n-oxide on the intermediate could be replaced by 4,6-dimethylpyrimidine carboxamide. vicriviroc had an excellent selectivity for ccr5 receptors over muscarinic and herg affinity was greatly reduced. phase i clinical trial of vicriviroc gave promising results, so a phase ii study in the treatment of naïve patients was initiated. the phase ii study was discontinued since there was a viral breakthrough in the vicriviroc group compared to the control group. these results suggested that vicriviroc was not effective in the treatment of treatment-naïve patients compared to current treatments. another phase ii clinical study was performed in treatment-experienced patients. the results were that vicriviroc did have strong antiviral activity but five instances of cancer among the participants were reported, however, the study was continued since there was lack of causal association of the malignancies and vicriviroc. in late 2009, vicriviroc was reported by the company to have entered phase ii studies in treatment for naïve patients and phase iii studies in treatment-experienced patients. maraviroc pfizer turned to high-throughput screening in their search for a good starting point for a small molecule ccr5 antagonist. their screening resulted in a compound